1
|
Attreed SE, Silva C, Rodriguez-Calzada M, Mogulothu A, Abbott S, Azzinaro P, Canning P, Skidmore L, Nelson J, Knudsen N, Medina GN, de los Santos T, Díaz-San Segundo F. Prophylactic treatment with PEGylated bovine IFNλ3 effectively bridges the gap in vaccine-induced immunity against FMD in cattle. Front Microbiol 2024; 15:1360397. [PMID: 38638908 PMCID: PMC11024232 DOI: 10.3389/fmicb.2024.1360397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2023] [Accepted: 03/11/2024] [Indexed: 04/20/2024] Open
Abstract
Foot-and-mouth disease (FMD) is a vesicular disease of cloven-hoofed animals with devastating economic implications. The current FMD vaccine, routinely used in enzootic countries, requires at least 7 days to induce protection. However, FMD vaccination is typically not recommended for use in non-enzootic areas, underscoring the need to develop new fast-acting therapies for FMD control during outbreaks. Interferons (IFNs) are among the immune system's first line of defense against viral infections. Bovine type III IFN delivered by a replication defective adenovirus (Ad) vector has effectively blocked FMD in cattle. However, the limited duration of protection-usually only 1-3 days post-treatment (dpt)-diminishes its utility as a field therapeutic. Here, we test whether polyethylene glycosylation (PEGylation) of recombinant bovine IFNλ3 (PEGboIFNλ3) can extend the duration of IFN-induced prevention of FMDV infection in both vaccinated and unvaccinated cattle. We treated groups of heifers with PEGboIFNλ3 alone or in combination with an adenovirus-based FMD O1Manisa vaccine (Adt-O1M) at either 3 or 5 days prior to challenge with homologous wild type FMDV. We found that pre-treatment with PEGboIFNλ3 was highly effective at preventing clinical FMD when administered at either time point, with or without co-administration of Adt-O1M vaccine. PEGboIFNλ3 protein was detectable systemically for >10 days and antiviral activity for 4 days following administration. Furthermore, in combination with Adt-O1M vaccine, we observed a strong induction of FMDV-specific IFNγ+ T cell response, demonstrating its adjuvanticity when co-administered with a vaccine. Our results demonstrate the promise of this modified IFN as a pre-exposure prophylactic therapy for use in emergency outbreak scenarios.
Collapse
Affiliation(s)
- Sarah E. Attreed
- Plum Island Animal Disease Center, Plains Area, Agricultural Research Service, U.S. Department of Agriculture, Greenport, NY, United States
| | - Christina Silva
- Plum Island Animal Disease Center, Plains Area, Agricultural Research Service, U.S. Department of Agriculture, Greenport, NY, United States
| | - Monica Rodriguez-Calzada
- Plum Island Animal Disease Center, Plains Area, Agricultural Research Service, U.S. Department of Agriculture, Greenport, NY, United States
- Oak Ridge Institute for Science and Education Plum Island Animal Disease Center Research Participation Program, Oak Ridge, TN, United States
| | - Aishwarya Mogulothu
- Plum Island Animal Disease Center, Plains Area, Agricultural Research Service, U.S. Department of Agriculture, Greenport, NY, United States
- Department of Pathobiology and Veterinary Science, University of Connecticut, Storrs, CT, United States
| | - Sophia Abbott
- Plum Island Animal Disease Center, Plains Area, Agricultural Research Service, U.S. Department of Agriculture, Greenport, NY, United States
- Animal Biosciences and Biotechnology Laboratory, Northeast Area, Agricultural Research Service, U.S. Department of Agriculture, Beltsville, MD, United States
| | - Paul Azzinaro
- Plum Island Animal Disease Center, Plains Area, Agricultural Research Service, U.S. Department of Agriculture, Greenport, NY, United States
| | | | | | - Jay Nelson
- Ambrx Biopharma, Inc., La Jolla, CA, United States
| | - Nick Knudsen
- Ambrx Biopharma, Inc., La Jolla, CA, United States
| | - Gisselle N. Medina
- Plum Island Animal Disease Center, Plains Area, Agricultural Research Service, U.S. Department of Agriculture, Greenport, NY, United States
- National Bio-and Agro-Defense Facility, Plains Area, Agricultural Research Service, U.S. Department of Agriculture, Manhattan, KS, United States
| | - Teresa de los Santos
- Plum Island Animal Disease Center, Plains Area, Agricultural Research Service, U.S. Department of Agriculture, Greenport, NY, United States
| | - Fayna Díaz-San Segundo
- Plum Island Animal Disease Center, Plains Area, Agricultural Research Service, U.S. Department of Agriculture, Greenport, NY, United States
- Office of Biodefense, Research Resources and Translational Research, National Institute of Allergy and Infectious Disease, Rockville, MD, United States
| |
Collapse
|
2
|
Puckette M, Primavera V, Martel E, Barrera J, Hurtle W, Clark B, Kamicker B, Zurita M, Brake D, Neilan J. Transiently Transfected Mammalian Cell Cultures: An Adaptable and Effective Platform for Virus-like Particle-Based Vaccines against Foot-and-Mouth Disease Virus. Viruses 2022; 14:v14050989. [PMID: 35632734 PMCID: PMC9147724 DOI: 10.3390/v14050989] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Revised: 05/03/2022] [Accepted: 05/05/2022] [Indexed: 01/13/2023] Open
Abstract
RNA viruses, such as foot-and-mouth disease virus (FMDV), have error-prone replication resulting in the continuous emergence of new viral strains capable of evading current vaccine coverage. Vaccine formulations must be regularly updated, which is both costly and technically challenging for many vaccine platforms. In this report, we describe a plasmid-based virus-like particle (VLP) production platform utilizing transiently transfected mammalian cell cultures that combines both the rapid response adaptability of nucleic-acid-based vaccines with the ability to produce intact capsid epitopes required for immunity. Formulated vaccines which employed this platform conferred complete protection from clinical foot-and-mouth disease in both swine and cattle. This novel platform can be quickly adapted to new viral strains and serotypes through targeted exchanges of only the FMDV capsid polypeptide nucleic acid sequences, from which processed structural capsid proteins are derived. This platform obviates the need for high biocontainment manufacturing facilities to produce inactivated whole-virus vaccines from infected mammalian cell cultures, which requires upstream expansion and downstream concentration of large quantities of live virulent viruses.
Collapse
Affiliation(s)
- Michael Puckette
- Plum Island Animal Disease Center, U.S. Department of Homeland Security Science and Technology Directorate, New York, NY 11944, USA; (W.H.); (J.N.)
- Correspondence: ; Tel.: +1-631-323-3176
| | - Victoria Primavera
- Plum Island Animal Disease Center, Leidos, New York, NY 11944, USA; (V.P.); (J.B.); (B.K.); (M.Z.)
- Plum Island Animal Disease Center, SAIC, New York, NY 11944, USA
| | - Erica Martel
- Plum Island Animal Disease Center Research Participation Program, Oak Ridge Institute for Science and Education, New York, NY 11944, USA; (E.M.); (B.C.)
| | - Jose Barrera
- Plum Island Animal Disease Center, Leidos, New York, NY 11944, USA; (V.P.); (J.B.); (B.K.); (M.Z.)
- Plum Island Animal Disease Center, SAIC, New York, NY 11944, USA
| | - William Hurtle
- Plum Island Animal Disease Center, U.S. Department of Homeland Security Science and Technology Directorate, New York, NY 11944, USA; (W.H.); (J.N.)
| | - Benjamin Clark
- Plum Island Animal Disease Center Research Participation Program, Oak Ridge Institute for Science and Education, New York, NY 11944, USA; (E.M.); (B.C.)
| | - Barbara Kamicker
- Plum Island Animal Disease Center, Leidos, New York, NY 11944, USA; (V.P.); (J.B.); (B.K.); (M.Z.)
- Plum Island Animal Disease Center, SAIC, New York, NY 11944, USA
| | - Mariceny Zurita
- Plum Island Animal Disease Center, Leidos, New York, NY 11944, USA; (V.P.); (J.B.); (B.K.); (M.Z.)
- Plum Island Animal Disease Center, SAIC, New York, NY 11944, USA
| | - David Brake
- BioQuest Associates, LLC, P.O. Box 787, Stowe, VT 05672, USA;
| | - John Neilan
- Plum Island Animal Disease Center, U.S. Department of Homeland Security Science and Technology Directorate, New York, NY 11944, USA; (W.H.); (J.N.)
| |
Collapse
|
3
|
Medina GN, de Los Santos T, Díaz-San Segundo F. Generation of Replication Deficient Human Adenovirus 5 (Ad5) Vectored FMD Vaccines. Methods Mol Biol 2022; 2465:155-175. [PMID: 35118621 DOI: 10.1007/978-1-0716-2168-4_9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Adenovirus vectors offer a convenient platform for the expression of antigens and have become an attractive system for vaccine development. Currently, the most successful approach to the development of new foot-and-mouth disease (FMD) vaccines has been the production of a replication-defective human serotype 5 adenovirus that delivers the capsid and capsid processing coding regions of FMD virus (FMDV) (Ad5-FMD). A specific construct for FMDV serotype A24 has been fully developed into a commercial product fulfilling the requirements of the Center of Veterinary Biologics (CVB) of the Animal and Plant Health Inspection Service (APHIS) of the U.S. Department of Agriculture (USDA), for commercialization in the USA. In this chapter, we describe a standard protocol for the generation and small-scale production of Ad5-FMDV serotype O1Manisa vaccines. We use directional cloning to introduce the FMDV O1Manisa capsid in the Ad5-Blue vector. This is followed by the linearization of the recombinant Ad5 with Pac I and transfection into HEK293 cells for rescue and propagation, and then by increased production and purification. Finally, purified recombinant virus is characterized by determining virus yield and expression of targeted antigen in specific cell type of interest.
Collapse
Affiliation(s)
- Gisselle N Medina
- Plum Island Animal Disease Center (PIADC), ARS, USDA, Greenport, NY, USA.
- National Bio and Agro-Defense Facility (NBAF), ARS, USDA, Manhattan, KS, USA.
| | | | | |
Collapse
|
4
|
Choudhury SM, Ma X, Dang W, Li Y, Zheng H. Recent Development of Ruminant Vaccine Against Viral Diseases. Front Vet Sci 2021; 8:697194. [PMID: 34805327 PMCID: PMC8595237 DOI: 10.3389/fvets.2021.697194] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Accepted: 10/04/2021] [Indexed: 01/21/2023] Open
Abstract
Pathogens of viral origin produce a large variety of infectious diseases in livestock. It is essential to establish the best practices in animal care and an efficient way to stop and prevent infectious diseases that impact animal husbandry. So far, the greatest way to combat the disease is to adopt a vaccine policy. In the fight against infectious diseases, vaccines are very popular. Vaccination's fundamental concept is to utilize particular antigens, either endogenous or exogenous to induce immunity against the antigens or cells. In light of how past emerging and reemerging infectious diseases and pandemics were handled, examining the vaccination methods and technological platforms utilized for the animals may provide some useful insights. New vaccine manufacturing methods have evolved because of developments in technology and medicine and our broad knowledge of immunology, molecular biology, microbiology, and biochemistry, among other basic science disciplines. Genetic engineering, proteomics, and other advanced technologies have aided in implementing novel vaccine theories, resulting in the discovery of new ruminant vaccines and the improvement of existing ones. Subunit vaccines, recombinant vaccines, DNA vaccines, and vectored vaccines are increasingly gaining scientific and public attention as the next generation of vaccines and are being seen as viable replacements to conventional vaccines. The current review looks at the effects and implications of recent ruminant vaccine advances in terms of evolving microbiology, immunology, and molecular biology.
Collapse
Affiliation(s)
- Sk Mohiuddin Choudhury
- State Key Laboratory of Veterinary Etiological Biology, National Foot and Mouth Disease Reference Laboratory, Key Laboratory of Animal Virology of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China
| | - XuSheng Ma
- State Key Laboratory of Veterinary Etiological Biology, National Foot and Mouth Disease Reference Laboratory, Key Laboratory of Animal Virology of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China
| | - Wen Dang
- State Key Laboratory of Veterinary Etiological Biology, National Foot and Mouth Disease Reference Laboratory, Key Laboratory of Animal Virology of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China
| | - YuanYuan Li
- Gansu Agricultural University, Lanzhou, China
| | - HaiXue Zheng
- State Key Laboratory of Veterinary Etiological Biology, National Foot and Mouth Disease Reference Laboratory, Key Laboratory of Animal Virology of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China
| |
Collapse
|
5
|
Ziraldo M, Bidart JE, Prato CA, Tribulatti MV, Zamorano P, Mattion N, D’Antuono AL. Optimized Adenoviral Vector That Enhances the Assembly of FMDV O1 Virus-Like Particles in situ Increases Its Potential as Vaccine for Serotype O Viruses. Front Microbiol 2020; 11:591019. [PMID: 33250878 PMCID: PMC7672010 DOI: 10.3389/fmicb.2020.591019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Accepted: 09/28/2020] [Indexed: 12/27/2022] Open
Abstract
Although replication-defective human adenovirus type 5 (Ad5) vectors that express in situ the capsid-encoding region of foot-and-mouth disease virus (FMDV) have been proven to be effective as vaccines in relevant species for several viral strains, the same result was not consistently achieved for the O1/Campos/Brazil/58 strain. In the present study, an optimization of the Ad5 system was explored and was proven to enhance the expression of FMDV capsid proteins and their association into virus-like particles (VLPs). Particularly, we engineered a novel Ad5 vector (Ad5[PVP2]OP) which harbors the foreign transcription unit in a leftward orientation relative to the Ad5 genome, and drives the expression of the FMDV sequences from an optimized cytomegalovirus (CMV) enhancer-promoter as well. The Ad5[PVP2]OP vaccine candidate also contains the amino acid substitutions S93F/Y98F in the VP2 protein coding sequence, predicted to stabilize FMD virus particles. Cells infected with the optimized vector showed an ∼14-fold increase in protein expression as compared to cells infected with an unmodified Ad5 vector tested in previous works. Furthermore, amino acid substitutions in VP2 protein allowed the assembly of FMDV O1/Campos/Brazil/58 VLPs. Evaluation of several serological parameters in inoculated mice with the optimized Ad5[PVP2]OP candidate revealed an enhanced vaccine performance, characterized by significant higher titers of neutralizing antibodies, as compared to our previous unmodified Ad5 vector. Moreover, 94% of the mice vaccinated with the Ad5[PVP2]OP candidate were protected from homologous challenge. These results indicate that both the optimized protein expression and the stabilization of the in situ generated VLPs improved the performance of Ad5-vectored vaccines against the FMDV O1/Campos/Brazil/58 strain and open optimistic expectations to be tested in target animals.
Collapse
Affiliation(s)
- Micaela Ziraldo
- Centro de Virología Animal, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina
| | - Juan E. Bidart
- Instituto de Virología e Innovaciones Tecnológicas, Centro de Investigaciones en Ciencias Veterinarias, Instituto Nacional de Tecnología Agropecuaria, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina
| | - Cecilia A. Prato
- Laboratorio de Inmunología Molecular, Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina
| | - María V. Tribulatti
- Laboratorio de Inmunología Molecular, Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina
| | - Patricia Zamorano
- Instituto de Virología e Innovaciones Tecnológicas, Centro de Investigaciones en Ciencias Veterinarias, Instituto Nacional de Tecnología Agropecuaria, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina
| | - Nora Mattion
- Centro de Virología Animal, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina
| | - Alejandra L. D’Antuono
- Centro de Virología Animal, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina
| |
Collapse
|
6
|
Jouneau L, Lefebvre DJ, Costa F, Romey A, Blaise-Boisseau S, Relmy A, Jaszczyszyn Y, Dard-Dascot C, Déjean S, Versillé N, Guitton E, Hudelet P, Curet M, De Clercq K, Bakkali-Kassimi L, Zientara S, Klonjkowski B, Schwartz-Cornil I. The antibody response induced FMDV vaccines in sheep correlates with early transcriptomic responses in blood. NPJ Vaccines 2020; 5:1. [PMID: 31908850 PMCID: PMC6941976 DOI: 10.1038/s41541-019-0151-3] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Accepted: 11/29/2019] [Indexed: 11/09/2022] Open
Abstract
Foot and mouth disease (FMD) is a highly contagious viral disease with high economic impact, representing a major threat for cloven-hooved mammals worldwide. Vaccines based on adjuvanted inactivated virus (iFMDV) induce effective protective immunity implicating antibody (Ab) responses. To reduce the biosafety constraints of the manufacturing process, a non-replicative human adenovirus type 5 vector encoding FMDV antigens (Ad5-FMDV) has been developed. Here we compared the immunogenicity of iFMDV and Ad5-FMDV with and without the ISA206VG emulsion-type adjuvant in sheep. Contrasted Ab responses were obtained: iFMDV induced the highest Ab levels, Ad5-FMDV the lowest ones, and ISA206VG increased the Ad5-FMDV-induced Ab responses to protective levels. Each vaccine generated heterogeneous Ab responses, with high and low responders, the latter being considered as obstacles to vaccine effectiveness. A transcriptomic study on total blood responses at 24 h post-vaccination revealed several blood gene module activities correlating with long-term Ab responses. Downmodulation of T cell modules’ activities correlated with high responses to iFMDV and to Ad5-FMDV+ISA206VG vaccines as also found in other systems vaccinology studies in humans and sheep. The impact of cell cycle activity depended on the vaccine types, as it positively correlated with higher responses to iFMDV but negatively to non-adjuvanted Ad5-FMDV. Finally an elevated B cell activity at 24 h correlated with high Ab responses to the Ad5-FMDV+ISA206VG vaccine. This study provides insights into the early mechanisms driving the Ab response induced by different vaccine regimens including Ad5 vectors and points to T cell modules as early biomarker candidates of different vaccine-type efficacy across species. Foot and mouth disease virus (FMDV) is a serious pathogen of cloven hoofed mammals and is of high economic and veterinary importance. Inactivated vaccine (iFMDV) is effective but difficult to produce because of high biosafety level requirements; non-replicating adenovirus vectors carrying key FMDV antigens (Ad5-FMDV) might therefore represent an attractive alternative. Isabelle Schwartz-Cornil and colleagues use sheep to systematically compare vaccination with adjuvanted iFMDV, adjuvanted Ad5-FMDV, or non-adjuvanted Ad5-FMDV. All vaccines produce neutralizing antibody responses which are stable to at least one year, however the iFMDV group elicits the strongest response, followed by the adjuvanted Ad5-FMDV. Ad5-FMDV alone produces weak antibody titers. Blood transcriptomic analysis performed in the first 24 h following vaccination identifies a reduced T cell gene expression module as a correlate of high neutralizing antibody titers. Blood gene expression might therefore offer insights into the mechanistic underpinnings of humoral immunity as well as provide useful biomarker correlates of protection.
Collapse
Affiliation(s)
- Luc Jouneau
- Université Paris-Saclay, INRA, VIM, Domaine de Vilvert, 78350 Jouy-en-Josas, France
| | - David J Lefebvre
- Sciensano, Scientific Direction of Infectious Diseases in Animals, Service for Exotic Viruses and Particular Diseases, Groeselenberg 99, 1180 Brussels, Belgium
| | - Fleur Costa
- Université Paris-Est, ANSES, Ecole Nationale Vétérinaire d'Alfort, INRA, Laboratoire de santé animale, UMR Virologie, Maisons-Alfort, France
| | - Aurore Romey
- Université Paris-Est, ANSES, Ecole Nationale Vétérinaire d'Alfort, INRA, Laboratoire de santé animale, UMR Virologie, Maisons-Alfort, France
| | - Sandra Blaise-Boisseau
- Université Paris-Est, ANSES, Ecole Nationale Vétérinaire d'Alfort, INRA, Laboratoire de santé animale, UMR Virologie, Maisons-Alfort, France
| | - Anthony Relmy
- Université Paris-Est, ANSES, Ecole Nationale Vétérinaire d'Alfort, INRA, Laboratoire de santé animale, UMR Virologie, Maisons-Alfort, France
| | - Yan Jaszczyszyn
- 4Université Paris-Saclay, Université Paris-Sud, CNRS, CEA, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette, France
| | - Cloelia Dard-Dascot
- 4Université Paris-Saclay, Université Paris-Sud, CNRS, CEA, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette, France
| | - Sébastien Déjean
- 5Université de Toulouse, Université Paul Sabatier, CNRS, Institut de Mathématiques de Toulouse, UMR5219, 31062 Toulouse Cedex, France
| | | | - Edouard Guitton
- INRA, Plate-Forme d'Infectiologie Expérimentale (PFIE), UE1277, 37380 Nouzilly, France
| | - Pascal Hudelet
- 8Merial S.A.S., 29 Avenue Tony Garnier, 69007 Lyon, France
| | - Marianne Curet
- 8Merial S.A.S., 29 Avenue Tony Garnier, 69007 Lyon, France
| | - Kris De Clercq
- Sciensano, Scientific Direction of Infectious Diseases in Animals, Service for Exotic Viruses and Particular Diseases, Groeselenberg 99, 1180 Brussels, Belgium
| | - Labib Bakkali-Kassimi
- Université Paris-Est, ANSES, Ecole Nationale Vétérinaire d'Alfort, INRA, Laboratoire de santé animale, UMR Virologie, Maisons-Alfort, France
| | - Stéphan Zientara
- Université Paris-Est, ANSES, Ecole Nationale Vétérinaire d'Alfort, INRA, Laboratoire de santé animale, UMR Virologie, Maisons-Alfort, France
| | - Bernard Klonjkowski
- Université Paris-Est, ANSES, Ecole Nationale Vétérinaire d'Alfort, INRA, Laboratoire de santé animale, UMR Virologie, Maisons-Alfort, France
| | | |
Collapse
|
7
|
Foot-and-Mouth Disease Virus: Immunobiology, Advances in Vaccines and Vaccination Strategies Addressing Vaccine Failures-An Indian Perspective. Vaccines (Basel) 2019; 7:vaccines7030090. [PMID: 31426368 PMCID: PMC6789522 DOI: 10.3390/vaccines7030090] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2019] [Revised: 07/26/2019] [Accepted: 07/30/2019] [Indexed: 12/21/2022] Open
Abstract
A mass vaccination campaign in India seeks to control and eventually eradicate foot-and-mouth disease (FMD). Biosanitary measures along with FMD monitoring are being conducted along with vaccination. The implementation of the FMD control program has drastically reduced the incidence of FMD. However, cases are still reported, even in regions where vaccination is carried out regularly. Control of FMD outbreaks is difficult when the virus remains in circulation in the vaccinated population. Various FMD risk factors have been identified that are responsible for FMD in vaccinated areas. The factors are discussed along with strategies to address these challenges. The current chemically inactivated trivalent vaccine formulation containing strains of serotype O, A, and Asia 1 has limitations including thermolability and induction of only short-term immunity. Advantages and disadvantages of several new-generation alternate vaccine formulations are discussed. It is unfeasible to study every incidence of FMD in vaccinated animals/areas in such a big country as India with its huge livestock population. However, at the same time, it is absolutely necessary to identify the precise reason for vaccination failure. Failure to vaccinate is one reason for the occurrence of FMD in vaccinated areas. FMD epidemiology, emerging and re-emerging virus strains, and serological status over the past 10 years are discussed to understand the impact of vaccination and incidences of vaccination failure in India. Other factors that are important in vaccination failure that we discuss include disrupted herd immunity, health status of animals, FMD carrier status, and FMD prevalence in other species. Recommendations to boost the search of alternate vaccine formulation, strengthen the veterinary infrastructure, bolster the real-time monitoring of FMD, as well as a detailed investigation and documentation of every case of vaccination failure are provided with the goal of refining the control program.
Collapse
|
8
|
Foot-and-mouth disease vaccines: recent updates and future perspectives. Arch Virol 2019; 164:1501-1513. [PMID: 30888563 DOI: 10.1007/s00705-019-04216-x] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2018] [Accepted: 03/16/2019] [Indexed: 02/07/2023]
Abstract
Foot-and-mouth disease (FMD) is a major worldwide viral disease in animals, affecting the national and international trade of livestock and animal products and leading to high economic losses and social consequences. Effective control measures of FMD involve prevention through vaccination with inactivated vaccines. These inactivated vaccines, unfortunately, require short-term protection and cold-chain and high-containment facilities. Major advances and pursuit of hot topics in vaccinology and vectorology are ongoing, involving peptide vaccines, DNA vaccines, live vector vaccines, and novel attenuated vaccines. DIVA capability and marker vaccines are very important in differentiating infected animals from vaccinated animals. This review focuses on updating the research progress of these novel vaccines, summarizing their merits and including ideas for improvement.
Collapse
|
9
|
Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine. Vaccine 2018; 36:7345-7352. [DOI: 10.1016/j.vaccine.2018.10.031] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2018] [Revised: 10/03/2018] [Accepted: 10/06/2018] [Indexed: 12/14/2022]
|
10
|
Yang L, Liu Z, Li J, He K, Kong L, Guo R, Liu W, Gao Y, Zhong J. Association of the expression of Th cytokines with peripheral CD4 and CD8 lymphocyte subsets after vaccination with FMD vaccine in Holstein young sires. Res Vet Sci 2018; 119:79-84. [DOI: 10.1016/j.rvsc.2018.05.017] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Revised: 05/13/2018] [Accepted: 05/23/2018] [Indexed: 12/29/2022]
|
11
|
de los Santos T, Diaz-San Segundo F, Rodriguez LL. The need for improved vaccines against foot-and-mouth disease. Curr Opin Virol 2018; 29:16-25. [DOI: 10.1016/j.coviro.2018.02.005] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Revised: 02/07/2018] [Accepted: 02/23/2018] [Indexed: 10/17/2022]
|
12
|
Barrera J, Schutta C, Pisano M, Grubman MJ, Brake DA, Miller T, Kamicker BJ, Olutunmbi F, Ettyreddy D, Brough DE, Butman BT, Neilan JG. Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine. Vaccine 2018; 36:1078-1084. [PMID: 29358056 DOI: 10.1016/j.vaccine.2018.01.026] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Revised: 01/08/2018] [Accepted: 01/09/2018] [Indexed: 11/30/2022]
Abstract
A foot-and-mouth disease (FMD) recombinant subunit vaccine formulated with a lipid/polymer adjuvant was evaluated in two vaccine efficacy challenge studies in steers. The vaccine active ingredient is a replication-deficient human adenovirus serotype 5 vector encoding the FMD virus (FMDV) A24/Cruzeiro/BRA/55 capsid (AdtA24). In the first study, AdtA24 formulated in ENABL® adjuvant was compared to a fourfold higher dose of AdtA24 without adjuvant. Steers vaccinated with AdtA24 + ENABL® adjuvant developed a significantly higher virus neutralizing test (VNT) antibody titer and an improved clinical response following FMDV A24/Cruzeiro/BRA/55 intradermal lingual challenge at 14 days post-vaccination (dpv) than steers vaccinated with the active ingredient alone. In the second study, vaccination with AdtA24 formulated in ENABL® at the same dose used in the first study, followed by FMDV A24/Cruzeiro/BRA/55 challenge on 7 or 14 dpv, prevented clinical FMD in all steers and conferred 90% protection against viremia. In addition, post-challenge FMDV titers in nasal samples from vaccinated steers compared to unvaccinated steers were significantly reduced. In both studies, none of the AdtA24 vaccinated steers developed antibodies to the FMDV non-structural proteins prior to challenge with FMDV, indicative of the capacity to differentiate infected from vaccinated animals (DIVA). These results demonstrate that administration of AdtA24 formulated in ENABL® adjuvant lowered the protective dose and prevented clinical FMD following exposure of vaccinated steers to virulent FMDV at 7 or 14 dpv.
Collapse
Affiliation(s)
- José Barrera
- The McConnell Group, Inc., Plum Island Animal Disease Center, P.O. Box 848, Greenport, NY 11944, United States
| | - Christopher Schutta
- U.S. Department of Homeland Security Science and Technology Directorate, Plum Island Animal Disease Center, P.O. Box 848, Greenport, NY 11944, United States
| | - Melia Pisano
- The McConnell Group, Inc., Plum Island Animal Disease Center, P.O. Box 848, Greenport, NY 11944, United States; Oak Ridge Institute for Science and Education, Plum Island Animal Disease Center Research Participation Program, Oak Ridge, TN, United States
| | - Marvin J Grubman
- U.S. Department of Agriculture, Agricultural Research Service, Foreign Animal Disease Research Unit, Plum Island Animal Disease Center, P.O. Box 848, Greenport, NY 11944, United States
| | - David A Brake
- BioQuest Associates, LLC, Plum Island Animal Disease Center, P.O. Box 848, Greenport, NY 11944, United States
| | - Timothy Miller
- Benchmark Biolabs, Inc., 421 West Industrial Lake Dr., Lincoln, NE 68528, United States
| | - Barbara J Kamicker
- Leidos, Plum Island Animal Disease Center, P.O. Box 848, Greenport, NY 11944, United States
| | - Femi Olutunmbi
- Oak Ridge Institute for Science and Education, Plum Island Animal Disease Center Research Participation Program, Oak Ridge, TN, United States
| | - Damodar Ettyreddy
- GenVec, Inc., 910 Clopper Road, Suite 220N, Gaithersburg, MD 20878, United States
| | - Douglas E Brough
- GenVec, Inc., 910 Clopper Road, Suite 220N, Gaithersburg, MD 20878, United States
| | - Bryan T Butman
- GenVec, Inc., 910 Clopper Road, Suite 220N, Gaithersburg, MD 20878, United States
| | - John G Neilan
- U.S. Department of Homeland Security Science and Technology Directorate, Plum Island Animal Disease Center, P.O. Box 848, Greenport, NY 11944, United States.
| |
Collapse
|
13
|
Puckette M, Clark BA, Smith JD, Turecek T, Martel E, Gabbert L, Pisano M, Hurtle W, Pacheco JM, Barrera J, Neilan JG, Rasmussen M. Foot-and-Mouth Disease (FMD) Virus 3C Protease Mutant L127P: Implications for FMD Vaccine Development. J Virol 2017; 91:e00924-17. [PMID: 28878081 PMCID: PMC5660475 DOI: 10.1128/jvi.00924-17] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2017] [Accepted: 08/23/2017] [Indexed: 01/23/2023] Open
Abstract
The foot-and-mouth disease virus (FMDV) afflicts livestock in more than 80 countries, limiting food production and global trade. Production of foot-and-mouth disease (FMD) vaccines requires cytosolic expression of the FMDV 3C protease to cleave the P1 polyprotein into mature capsid proteins, but the FMDV 3C protease is toxic to host cells. To identify less-toxic isoforms of the FMDV 3C protease, we screened 3C mutants for increased transgene output in comparison to wild-type 3C using a Gaussia luciferase reporter system. The novel point mutation 3C(L127P) increased yields of recombinant FMDV subunit proteins in mammalian and bacterial cells expressing P1-3C transgenes and retained the ability to process P1 polyproteins from multiple FMDV serotypes. The 3C(L127P) mutant produced crystalline arrays of FMDV-like particles in mammalian and bacterial cells, potentially providing a practical method of rapid, inexpensive FMD vaccine production in bacteria.IMPORTANCE The mutant FMDV 3C protease L127P significantly increased yields of recombinant FMDV subunit antigens and produced virus-like particles in mammalian and bacterial cells. The L127P mutation represents a novel advancement for economical FMD vaccine production.
Collapse
Affiliation(s)
- Michael Puckette
- U.S. Department of Homeland Security Science and Technology Directorate, Plum Island Animal Disease Center, Greenport, New York, USA
- Leidos, Inc., Plum Island Animal Disease Center, Greenport, New York, USA
- Oak Ridge Institute for Science and Education, Plum Island Animal Disease Center Research Participation Program, Oak Ridge, Tennessee, USA
| | - Benjamin A Clark
- Leidos, Inc., Plum Island Animal Disease Center, Greenport, New York, USA
- Oak Ridge Institute for Science and Education, Plum Island Animal Disease Center Research Participation Program, Oak Ridge, Tennessee, USA
| | - Justin D Smith
- Leidos, Inc., Plum Island Animal Disease Center, Greenport, New York, USA
- Oak Ridge Institute for Science and Education, Plum Island Animal Disease Center Research Participation Program, Oak Ridge, Tennessee, USA
| | - Traci Turecek
- Leidos, Inc., Plum Island Animal Disease Center, Greenport, New York, USA
| | - Erica Martel
- Oak Ridge Institute for Science and Education, Plum Island Animal Disease Center Research Participation Program, Oak Ridge, Tennessee, USA
| | - Lindsay Gabbert
- Leidos, Inc., Plum Island Animal Disease Center, Greenport, New York, USA
| | - Melia Pisano
- Leidos, Inc., Plum Island Animal Disease Center, Greenport, New York, USA
| | - William Hurtle
- U.S. Department of Homeland Security Science and Technology Directorate, Plum Island Animal Disease Center, Greenport, New York, USA
| | - Juan M Pacheco
- Oak Ridge Institute for Science and Education, Plum Island Animal Disease Center Research Participation Program, Oak Ridge, Tennessee, USA
| | - José Barrera
- Leidos, Inc., Plum Island Animal Disease Center, Greenport, New York, USA
| | - John G Neilan
- U.S. Department of Homeland Security Science and Technology Directorate, Plum Island Animal Disease Center, Greenport, New York, USA
| | - Max Rasmussen
- U.S. Department of Homeland Security Science and Technology Directorate, Plum Island Animal Disease Center, Greenport, New York, USA
| |
Collapse
|
14
|
Fernandez-Sainz I, Medina GN, Ramirez-Medina E, Koster MJ, Grubman MJ, de Los Santos T. Adenovirus-vectored foot-and-mouth disease vaccine confers early and full protection against FMDV O1 Manisa in swine. Virology 2016; 502:123-132. [PMID: 28039799 DOI: 10.1016/j.virol.2016.12.021] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2016] [Revised: 12/13/2016] [Accepted: 12/19/2016] [Indexed: 10/20/2022]
Abstract
A human adenovirus (Ad5) vectored foot-and-mouth disease virus (FMDV) O1-Manisa subunit vaccine (Ad5-O1Man) was engineered to deliver FMDV O1-Manisa capsid and capsid-processing proteins. Swine inoculated with Ad5-O1Man developed an FMDV-specific humoral response as compared to animals inoculated with an empty Ad5-vector. Vaccinated animals were completely protected against homologous challenge at 7 or 21 days post-vaccination. Potency studies exhibited a PD50 of about 107 pfu/animal while a dose of 4×107pfu/animal fully protected swine against FMDV intradermal challenge. In-vitro cross-neutralization analysis distinctly predicted that swine vaccinated with Ad5-O1Man would be protected against challenge with homologous FMDV O1Man Middle East-South Asia (ME-SA) topotype and also against recent outbreak strains of Mya-98 South East Asia (SEA) lineage including O1-UK-2001 and O1-South Korea-2010. These results indicate that recombinant Ad5-O1Man is an effective, safe and cross-reacting vaccine that could potentially be used preventively and in outbreak situations, to control FMDV O Mya-98 lineage in swine.
Collapse
Affiliation(s)
- Ignacio Fernandez-Sainz
- Plum Island Animal Disease Center, ARS, USDA, Greenport, NY 11944, USA; Department of Pathobiology and Veterinary Science, University of Connecticut, Storrs, CT 06269, USA
| | - Gisselle N Medina
- Plum Island Animal Disease Center, ARS, USDA, Greenport, NY 11944, USA; ORISE-PIADC Research Participation Program, Oak Ridge, TN 37831, USA
| | - Elizabeth Ramirez-Medina
- Department of Pathobiology and Veterinary Science, University of Connecticut, Storrs, CT 06269, USA; ORISE-PIADC Research Participation Program, Oak Ridge, TN 37831, USA
| | - Marla J Koster
- Plum Island Animal Disease Center, ARS, USDA, Greenport, NY 11944, USA
| | - Marvin J Grubman
- Plum Island Animal Disease Center, ARS, USDA, Greenport, NY 11944, USA
| | | |
Collapse
|
15
|
Diaz-San Segundo F, Medina GN, Stenfeldt C, Arzt J, de Los Santos T. Foot-and-mouth disease vaccines. Vet Microbiol 2016; 206:102-112. [PMID: 28040311 DOI: 10.1016/j.vetmic.2016.12.018] [Citation(s) in RCA: 83] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2016] [Revised: 12/04/2016] [Accepted: 12/15/2016] [Indexed: 12/20/2022]
Abstract
Foot-and-mouth disease (FMD) is a highly contagious disease of cloven-hoofed animals. The disease affects many areas of the world, often causing extensive epizootics in livestock, mostly farmed cattle and swine, although sheep, goats and many wild species are also susceptible. In countries where food and farm animals are essential for subsistence agriculture, outbreaks of FMD seriously impact food security and development. In highly industrialized developed nations, FMD endemics cause economic and social devastation mainly due to observance of health measures adopted from the World Organization for Animal Health (OIE). High morbidity, complex host-range and broad genetic diversity make FMD prevention and control exceptionally challenging. In this article we review multiple vaccine approaches developed over the years ultimately aimed to successfully control and eradicate this feared disease.
Collapse
Affiliation(s)
- Fayna Diaz-San Segundo
- Foreign Animal Disease Research Unit (FADRU), Plum Island Animal Disease Center (PIADC), Agricultural Research Service (ARS), United States Department of Agriculture (USDA), Greenport, New York, USA; Department of Pathobiology and Veterinary Science, CANR, University of Connecticut, Storrs, CT 06269, USA.
| | - Gisselle N Medina
- Foreign Animal Disease Research Unit (FADRU), Plum Island Animal Disease Center (PIADC), Agricultural Research Service (ARS), United States Department of Agriculture (USDA), Greenport, New York, USA; PIADC Research Participation Program, Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA
| | - Carolina Stenfeldt
- Foreign Animal Disease Research Unit (FADRU), Plum Island Animal Disease Center (PIADC), Agricultural Research Service (ARS), United States Department of Agriculture (USDA), Greenport, New York, USA; PIADC Research Participation Program, Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA
| | - Jonathan Arzt
- Foreign Animal Disease Research Unit (FADRU), Plum Island Animal Disease Center (PIADC), Agricultural Research Service (ARS), United States Department of Agriculture (USDA), Greenport, New York, USA
| | - Teresa de Los Santos
- Foreign Animal Disease Research Unit (FADRU), Plum Island Animal Disease Center (PIADC), Agricultural Research Service (ARS), United States Department of Agriculture (USDA), Greenport, New York, USA.
| |
Collapse
|